958 related articles for article (PubMed ID: 16712662)
21. Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line.
Jeong H; Kim YR; Kim KN; Choe JG; Chung JK; Kim MK
Nucl Med Biol; 2006 Oct; 33(7):875-82. PubMed ID: 17045167
[TBL] [Abstract][Full Text] [Related]
22. Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells.
Kim KI; Kang JH; Chung JK; Lee YJ; Jeong JM; Lee DS; Lee MC
J Nucl Med; 2007 Sep; 48(9):1553-61. PubMed ID: 17704247
[TBL] [Abstract][Full Text] [Related]
23. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients.
Schlumberger M; Lacroix L; Russo D; Filetti S; Bidart JM
Nat Clin Pract Endocrinol Metab; 2007 Mar; 3(3):260-9. PubMed ID: 17315034
[TBL] [Abstract][Full Text] [Related]
24. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome.
Walter MA; Christ-Crain M; Eckard B; Schindler C; Nitzsche EU; Müller-Brand J; Müller B
Eur J Clin Invest; 2004 May; 34(5):365-70. PubMed ID: 15147334
[TBL] [Abstract][Full Text] [Related]
25. Radioiodide uptake and sodium iodide symporter expression in breast carcinoma.
Damle AA; Narkar AA; Badwe RA
Indian J Exp Biol; 2011 Jun; 49(6):416-22. PubMed ID: 21702220
[TBL] [Abstract][Full Text] [Related]
26. Establishment and characterization of a breast cancer cell line expressing Na+/I- symporters for radioiodide concentrator gene therapy.
Nakamoto Y; Saga T; Misaki T; Kobayashi H; Sato N; Ishimori T; Kosugi S; Sakahara H; Konishi J
J Nucl Med; 2000 Nov; 41(11):1898-904. PubMed ID: 11079502
[TBL] [Abstract][Full Text] [Related]
27. Predictive role of nontumoral sodium iodide symporter activity and preoperative thyroid characteristics in remission process of thyroid cancer patients.
Yildirim-Poyraz N; Yazgan A; Ozdemir E; Gozalan A; Keskin M; Ersoy R; Turkolmez S; Cakir B
Ann Nucl Med; 2014 Aug; 28(7):623-31. PubMed ID: 24823701
[TBL] [Abstract][Full Text] [Related]
28. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression.
Cengic N; Baker CH; Schütz M; Göke B; Morris JC; Spitzweg C
J Clin Endocrinol Metab; 2005 Aug; 90(8):4457-64. PubMed ID: 15941870
[TBL] [Abstract][Full Text] [Related]
29. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma.
Pluijmen MJ; Eustatia-Rutten C; Goslings BM; Stokkel MP; Arias AM; Diamant M; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2003 Apr; 58(4):428-35. PubMed ID: 12641625
[TBL] [Abstract][Full Text] [Related]
30. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.
Kogai T; Taki K; Brent GA
Endocr Relat Cancer; 2006 Sep; 13(3):797-826. PubMed ID: 16954431
[TBL] [Abstract][Full Text] [Related]
32. Lithium as an adjuvant in the postoperative ablation of remnant tissue in low-risk thyroid carcinoma.
Yamazaki CA; Padovani RP; Biscolla RP; Ikejiri ES; Marchetti RR; Castiglioni ML; Matsumura LK; Maciel RM; Furlanetto RP
Thyroid; 2012 Oct; 22(10):1002-6. PubMed ID: 22953991
[TBL] [Abstract][Full Text] [Related]
33. The rat sodium iodide symporter gene permits more effective radioisotope concentration than the human sodium iodide symporter gene in human and rodent cancer cells.
Heltemes LM; Hagan CR; Mitrofanova EE; Panchal RG; Guo J; Link CJ
Cancer Gene Ther; 2003 Jan; 10(1):14-22. PubMed ID: 12489024
[TBL] [Abstract][Full Text] [Related]
34. Gene therapy with sodium/iodide symporter in hepatocarcinoma.
Haberkorn U
Exp Clin Endocrinol Diabetes; 2001; 109(1):60-2. PubMed ID: 11573143
[TBL] [Abstract][Full Text] [Related]
35. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy.
Giovanella L; Ceriani L; Ghelfo A; Maffioli M; Keller F
Clin Endocrinol (Oxf); 2007 Oct; 67(4):547-51. PubMed ID: 17561976
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of I131 ablation therapy using different doses as determined by postoperative thyroid scan uptake in patients with differentiated thyroid cancer.
Zidan J; Hefer E; Iosilevski G; Drumea K; Stein ME; Kuten A; Israel O
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1330-6. PubMed ID: 15275717
[TBL] [Abstract][Full Text] [Related]
37. [Lithium as an adjuvant in the radioiodine therapy of thyroid cancer].
Schraube P; Kimmig B; zum Winkel K
Nuklearmedizin; 1984 Jun; 23(3):151-4. PubMed ID: 6435095
[TBL] [Abstract][Full Text] [Related]
38. In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral gliomas.
Cho JY; Shen DH; Yang W; Williams B; Buckwalter TL; La Perle KM; Hinkle G; Pozderac R; Kloos R; Nagaraja HN; Barth RF; Jhiang SM
Gene Ther; 2002 Sep; 9(17):1139-45. PubMed ID: 12170377
[TBL] [Abstract][Full Text] [Related]
39. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
Hoftijzer H; Heemstra KA; Morreau H; Stokkel MP; Corssmit EP; Gelderblom H; Weijers K; Pereira AM; Huijberts M; Kapiteijn E; Romijn JA; Smit JW
Eur J Endocrinol; 2009 Dec; 161(6):923-31. PubMed ID: 19773371
[TBL] [Abstract][Full Text] [Related]
40. High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism.
Romão R; Rubio IG; Tomimori EK; Camargo RY; Knobel M; Medeiros-Neto G
Thyroid; 2009 Sep; 19(9):945-51. PubMed ID: 19678745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]